WALTHAM, Mass. One of the world's leading research and advisory firms focusing on healthcare insights and analysis acquired a provider of specialized, syndicated market research in clinically complex, small to mid-size pharmaceutical markets.
The acquisition of Exton, Pa.-based BioTrends by Waltham, Mass.-based Decision Resources will result in a significant expansion of Decision Resources' portfolio planning segment of the biopharma business unit.
Jason LaBonte, Ph.D., newly appointed COO, Decision Resources' biopharma portfolio planning and optimization said, "This important acquisition expands the breadth of our disease coverage. BioTrends' deep clinical intimacy with specialized pharmaceutical markets and primary research-focused model enhances our high-value offerings to the biopharma industry."
BioTrends is particularly well-known in the nephrology market, offering unique insights on drugs in that market. They also cover dermatology, gastroenterology, immunology/infectious disease and rheumatology markets and, as the newest company in the Decision Resources, Inc. portfolio, plan to expand their coverage of diseases.
"We are excited to begin our next wave of growth as a Decision Resources, Inc. company," said Jennifer Robinson, president of BioTrends. "We bring to the table an emphasis on quality and a level of detail in our syndicated research that is second-to-none."
BioTrends will remain headquartered in Exton, Pa.